Description:
Multiplate®GpIIb/IIIaAntagoNIST isareagentkit foruseasquality controlinplateletaggregationstudiesontheMultiplate®Analyzer. TheGPIIb/IIIaAntagonistblockstheGPIIb/IIIareceptorandleadstoabolishedaggregationinallMultiplatetests.
GpIIb/IIIaantagonistinhibitsthefibrinogen receptorsoftheplateletsthuspreventingtheiradhesion ontothesensorwiresoftheMultiplate testcell.The reagentisemployedincombinationwiththeMultiplate® activatingreagentsTRAPtest,ASPItest,COLtestand ADPtest.AdditionofGpIIb/IIIaantagonisttotheblood sampleleadstostronglyreducedaggregationin TRAPtest,ADPtest,ASPItestandCOLtest.
Pleasenotethecatalog#forMultiplate®GpIIb/IIIaAntagonistReagenthaschangedto08115869001.Youmayhavepreviouslyorderedthisundercatalog#sMP0280 or06675948190.
KitComposition:
Reagents, StorageandStABIlity
- 08115869001:Multiplate® GpIIb/IIIaantagonist,synthetic GpIIb/IIIaantagonist(molecularweight495g/molina concentrationof50µg/ml),3x0.5ml,liquid,readyfor use.
Nolongeravailable
- MP0520:Multiplate® GpIIb/IIIaantagonist,synthetic GpIIb/IIIaantagonist(molecularweight495g/molina concentrationof50µg/ml),1x0.5ml,liquid,readyfor use.
UnopenedvialsoftheGpIIb/IIIaantagonistare stableuntiltheexpiry dateprintedontheviallabelwhenstoredstoredat2-8°C.Vialsshouldbestoredinanuprightposition. Stable30daysafteropeningwhenstoredat2-8°C.
MeasurementPrinciple:
GpIIb/IIIaantagonistcontainsasyntheticinhibitoroftheplateletGpIIb/IIIareceptorwithamolecularweightof 495g/molataconcentrationof50µg/ml. BlockingtheGpIIb/IIIareceptorleadstoabolished aggregationintheMultiplate tests.Thisallowsthe assessmentofapositivecontrol(stronglyinhibited aggregation)inalltests. FurThermoreunspecificeffectsofchemicalspresentin thesampleontotheMultiplate sensorscanbe elucidated(e.g.additionofoxidativesubstancesintothe blood).
NormallywhentheGpIIb/IIIaantagonistis addedtothesamplenosignificantimpedancechange duringtheanalysisisrecorded,becausethebindingof plateletsontothesensorwiresisblocked.Ifasignificant increaseordecreaseofimpedanceisstillrecordedwhen theGpIIb/IIIaantagonistisaddedtothesample,this suggestsunspecificdirecteffectsofsubstancesinthe bloodorsubstancesinreagents(thatwerenotdeveloped byVerumDiagnosticaGmbH)ontothesensorwires(e.g. oxidatingeffects).
